Proactively manage your pharmacy inventory
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Manage your formulary budget
Find generic entry opportunities
Drug patents …
… from Kazakhstan to Kalamazoo
Anticipate generic drug launch
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Mixable combination for generating a suspension of stable microbubbles for ultrasonic imaging|
|Abstract:||Gas or air filled microbubble suspensions in aqueous phases usable as imaging contrast agents in ultrasonic echography. They contain laminarized surfactants and, optionally, hydrophilic stabilizers. The laminarized surfactants can be in the form of liposomes. The suspensions are obtained by exposing the laminarized surfactants to air or a gas before or after admixing with an aqueous phase.|
|Inventor(s):||Schneider; Michel (Troinex, CH), Yan; Feng (Carouge, CH), Grenier; Pascal (late of Ambilly, FR), Puginier; Jerome (Le Chable-Beaumont, FR), Barrau; Marie-Bernadette (Geneve, CH), Bussat; Philippe (Feigeres, FR), Hybl; Eva (Heidelberg, DE), Bichon; Daniel (Montpellier, FR)|
|Assignee:||Bracco International B.V. (Amsterdam, NL)|
|Filing Date:||Aug 01, 2000|
|Claims:||1. A mixable combination for generating a suspension of stable microbubbles for use in ultrasonic imaging, said combination comprising: (a) a dry pulverulent formulation comprising at least one film forming surfactant and a hydrophilic stabilizer in the presence of air or other entrappable gas, the film forming surfactant being a saturated phospholipid in lamellar or laminar form and capable of generating a suspension of stabilized air or gas microbubbles when brought into contact with an aqueous carrier phase; and (b) an aqueous carrier phase mixable with said dry formulation, said dry formulation and said aqueous carrier phase being mixable with each other to produce said suspension of stable microbubbles. |
2. The mixable combination of claim 1, wherein the saturated phospholipid is selected from the group consisting of phosphatidic acid, phosphatidyl-choline, phosphatidylethanolamine, phosphatidylserine, phosphatidyl-glycerol, phosphatidylinositol, cardiolipin and sphyngomyelin.
3. The mixable combination of claim 2, wherein the formulation further contains a substance selected from the group consisting of dicetylphosphate, cholesterol, ergosterol, phytosterol, sitosterol, lanosterol, tocopterol, propyl gallate, ascorbyl palmitate and butylated hydroxy-toluene.
4. The mixable combination of claim 1, further containing dissolved viscosity enhancers or stabilizers selected from linear and cross-linked poly- and oligo-saccharides, sugars, hydrophilic polymers and iodinated X-ray contrast agents in a weight ratio to the surfactants comprised between about 1:5 to 100:1.
5. The mixable combination of claim 1, wherein the formulation comprises up to 50% by weight of non-laminar surfactants selected from the group consisting from fatty acids, esters and ethers of fatty acids and alcohols with polyols, polyalkylene.
6. The mixable combination of claim 1, wherein the hydrophilic stabilizer is a hydrosoluble protein.
7. The mixable combination of claim 1, wherein the hydrophilic stabilizer is a polypeptide.
8. The mixable combination of claim 1, wherein the hydrophilic stabilizer is a sugar.
9. The mixable combination of claim 1, wherein the hydrophilic stabilizer is a poly- or oligo-saccharide.
10. The mixable combination of claim 1, wherein the hydrophilic stabilizer is a hydrophilic polymer.
11. The mixable combination of claim 1, wherein the dry pulverulent formulation comprises freeze-dried liposomes.
12. The mixable combination of claim 1, wherein the size of most microbubbles is below 50 .mu.m.
13. The mixable combination of claim 12, wherein the size of most microbubbles is below 10 .mu.m.
14. The mixable combination of claim 1, wherein the suspension contains about 10.sup.8 -10.sup.9 bubbles of 0.5-10 .mu.m size/ml.
15. The mixable combination of claim 1, wherein the entrappable gas is nitrogen or carbon dioxide.
16. The mixable combination of claim 1, wherein the entrappable gas is argon or methane.
17. The mixable combination of claim 1, wherein the entrappable gas is .sup.81 krypton or .sup.133 xenon.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.